ContributorsPublishersAdvertisers

Regorafenib Plus Pembrolizumab Misses PFS End Point in Microsatellite Stable CRC

onclive.com
 2022-01-22

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial. Pembrolizumab (Keytruda) plus regorafenib (Stivarga) failed to demonstrate a significant improvement in progression-free survival (PFS) in pretreated patients...

www.onclive.com

Comments / 0

Comments / 0